885051-90-1

Basic information

• Product Name: Pegloticase
• Synonyms: Pegloticase
• CAS NO: 885051-90-1
• Mol File: 885051-90-1.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pegloticase(CAS DataBase Reference)
• NIST Chemistry Reference: Pegloticase(885051-90-1)
• EPA Substance Registry System: Pegloticase(885051-90-1)

Safety Data

• Hazardous Substances Data: 885051-90-1(Hazardous Substances Data)

Usage

Description

Pegloticase is a recombinant form of the enzyme uricase, which is not naturally found in humans but is present in most mammals. It is a medication specifically designed to treat chronic gout in adults who have not responded to other treatments. This enzyme works by converting uric acid in the body into a substance that can be easily excreted by the kidneys, thereby reducing the levels of uric acid that contribute to gout symptoms.

Uses

Used in Pharmaceutical Industry:
Pegloticase is used as a therapeutic agent for the treatment of chronic gout in adults who have not responded well to other treatments. It is administered as an intravenous infusion, typically every two weeks, to help manage the condition by reducing uric acid levels in the body.
The use of pegloticase is primarily for the following reasons:
1. To provide an alternative treatment option for patients with chronic gout who have not found relief with conventional therapies.
2. To reduce the levels of uric acid in the body, which is a key factor in the development of gout symptoms and complications.
3. To facilitate the excretion of uric acid by converting it into a more soluble form that can be easily eliminated by the kidneys.
Common side effects associated with the use of pegloticase include infusion reactions, gout flares, and allergic reactions. Due to its potential side effects and the specific patient population it targets, pegloticase is only available by prescription and is usually considered a last-resort treatment for severe cases of gout.